1st Quarter - Termination
HASHEMI STRATEGIC ADVISORS for ULTRAGENYX
Client
Income
$30,000
Expenses
—
Terminated
Mar 11, 2024
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Rare and Ultrarare diseases Orphan Drug Act (DOA) Pediatric Priority Review Voucher (PPRV)
| Lobbyist | Covered position, as disclosed |
|---|---|
| COOKAB HASHEMI | — |
Medical/Disease Research/Clinical Labs MED
Rare and Ultrarare genetic diseases
| Lobbyist | Covered position, as disclosed |
|---|---|
| COOKAB HASHEMI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.